论文部分内容阅读
第131届美国神经病学会(ANA)年会于2006年8～11日在美国芝加哥举行,会上代表们报告的几个关于神经系统疾病治疗方面的研究引人注目。新型帕金森病贴片Alabama大学的Ray Watts报告,帕金森病患者每日贴敷一贴经皮rotigotine贴片可以将早期症状控制至少85周。rotigotine贴片试验是一个开放性延长试验,使用的透皮贴片含有2～6mg的多巴胺激动剂rotigotine。在延长试验前．研究人员首先在患者身上进行了6个月的贴敷制剂与安慰剂效果比较试验。期间,当137名患者贴敷贴片后,帕金森病评定量表(unified parkinson’s djseaSe rating scale,UPDRS)的分数立即减少了7点．并且在6个月后,治疗组的患者评定量表分数仍然保持在基线4点以下；在贴敷安慰剂的79名对照组患
The 131st annual meeting of the American Academy of Neurology (ANA) took place in Chicago, United States, from August 8 to 11, 2006. Several studies reported by deputies on the treatment of neurological diseases have drawn attention. New Parkinson’s Disease Patches Ray Watts at Alabama University reported that the daily application of a percutaneous rotigotine patch to patients with Parkinson’s disease can control early symptoms for at least 85 weeks. The rotigotine patch test is an open-label extension test using a transdermal patch containing 2 to 6 mg of the dopamine agonist rotigotine. Before extending the test. The researchers first performed a six-month patch-to-patient comparison of placebo efficacy on patients. During the 137-patient patch, the score of the unified parkinson’s djseaSe rating scale (UPDRS) was immediately reduced by 7 points. And after 6 months, the treatment group’s patient rating scale remained below baseline at 4 points; in the 79 placebo-treated control group